Marlborough biotech firm Advanced Cell Technology said it has picked up $30 million in capital through a common stock purchase agreement with a Chicago-based investment firm. The deal, with Lincoln ...

It’s only October, and Oregon already has its first conference championship haul of the year. The Ducks’ men’s and women’s cross country... WASHINGTON (KRT) ­ A Massachusetts company said Sunday that ...

The AMT designation gives Cellares’ clients using the Cell Shuttle priority review with the FDA leading to accelerated regulatory filings SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the ...

Researchers from Xi'an Jiaotong-Liverpool University (XJTLU) in China have developed a streamlined process that makes it ...

Ocata Therapeutics of Marlborough, which researches treatments for eye diseases, has agreed to be sold to Astellas Pharma Inc. of Japan for $379 million, the two companies announced late Monday.